These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 24088080)

  • 1. Immunotherapy for pulmonary TB: antimicrobial peptides and their inducers.
    Rivas-Santiago CE; Hernández-Pando R; Rivas-Santiago B
    Immunotherapy; 2013 Oct; 5(10):1117-26. PubMed ID: 24088080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-arginine and vitamin D: novel adjunctive immunotherapies in tuberculosis.
    Ralph AP; Kelly PM; Anstey NM
    Trends Microbiol; 2008 Jul; 16(7):336-44. PubMed ID: 18513971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of antimicrobial peptides in host defense against mycobacterial infections.
    Méndez-Samperio P
    Peptides; 2008 Oct; 29(10):1836-41. PubMed ID: 18582513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D: emerging roles in infection and immunity.
    Bartley J
    Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1359-69. PubMed ID: 21133662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial peptide elicitors: new hope for the post-antibiotic era.
    Prado Montes de Oca E
    Innate Immun; 2013 Jun; 19(3):227-41. PubMed ID: 23160387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using antimicrobial host defense peptides as anti-infective and immunomodulatory agents.
    Kruse T; Kristensen HH
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):887-95. PubMed ID: 19053901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for TB.
    Doherty TM
    Immunotherapy; 2012 Jun; 4(6):629-47. PubMed ID: 22788130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammalian host defense peptides and their implication on combating Leishmania infection.
    Abdossamadi Z; Seyed N; Rafati S
    Cell Immunol; 2016 Nov; 309():23-31. PubMed ID: 27729107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antimicrobial peptide elicitors: a potential strategy against infections].
    Prado-Montes de Oca E
    Gac Med Mex; 2009; 145(3):241-3. PubMed ID: 19685832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shortening the 'short-course' therapy- insights into host immunity may contribute to new treatment strategies for tuberculosis.
    Schön T; Lerm M; Stendahl O
    J Intern Med; 2013 Apr; 273(4):368-82. PubMed ID: 23331325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The re-emergence of tuberculosis.
    Porter JD; McAdam KP
    Annu Rev Public Health; 1994; 15():303-23. PubMed ID: 8054087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis.
    Rivas-Santiago B; Rivas Santiago CE; Castañeda-Delgado JE; León-Contreras JC; Hancock RE; Hernandez-Pando R
    Int J Antimicrob Agents; 2013 Feb; 41(2):143-8. PubMed ID: 23141114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cationic antimicrobial peptides: from innate immunity study to drug development. Up date].
    Andrès E; Dimarcq JL
    Med Mal Infect; 2007 Apr; 37(4):194-9. PubMed ID: 17306486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunct immune therapy of first-diagnosed TB, relapsed TB, treatment-failed TB, multidrug-resistant TB and TB/HIV.
    Butov DA; Efremenko YV; Prihoda ND; Yurchenko LI; Sokolenko NI; Arjanova OV; Stepanenko AL; Butova TS; Zaitzeva SS; Jirathitikal V; Bourinbaiar AS; Kutsyna GA
    Immunotherapy; 2012 Jul; 4(7):687-95. PubMed ID: 22853755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis: the return of an old enemy.
    Collins FM
    Crit Rev Microbiol; 1993; 19(1):1-16. PubMed ID: 8481210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycobacterium tuberculosis components stimulate production of the antimicrobial peptide hepcidin.
    Sow FB; Nandakumar S; Velu V; Kellar KL; Schlesinger LS; Amara RR; Lafuse WP; Shinnick TM; Sable SB
    Tuberculosis (Edinb); 2011 Jul; 91(4):314-21. PubMed ID: 21482189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy for MDR-TB (multi-drug resistant tuberculosis)--its feasibility].
    Tsuyuguchi I
    Kekkaku; 1999 Jun; 74(6):479-91. PubMed ID: 10423959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.